This post was originally published on this site
Philip Morris on Sunday sweetened its offer for Vectura, which makes inhaled treatments, to 165 pence per share, surpassing Carlyle’s final 155 pence proposal.
Vectura said it considered the terms of the Philip Morris offer to be fair and reasonable, and its board plans to unanimously recommend the bid to shareholders.
